168 related articles for article (PubMed ID: 17685864)
21. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials.
Nawrocki S; Murawa P; Malicki J; Kapcinska M; Gryska K; Izycki D; Kaczmarek A; Laciak M; Czapczyk A; Karczewska A; Rose-John S; Mackiewicz A
Immunol Lett; 2000 Sep; 74(1):81-6. PubMed ID: 10996632
[TBL] [Abstract][Full Text] [Related]
22. Cell based cancer vaccines: regulatory and commercial development.
Copier J; Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for melanoma.
Kim CJ; Dessureault S; Gabrilovich D; Reintgen DS; Slingluff CL
Cancer Control; 2002; 9(1):22-30. PubMed ID: 11907463
[TBL] [Abstract][Full Text] [Related]
24. Cancer vaccines.
Chekhun VF
Exp Oncol; 2008 Jun; 30(2):90. PubMed ID: 18680872
[No Abstract] [Full Text] [Related]
25. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
26. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
28. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
Obeid J; Hu Y; Slingluff CL
Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060
[TBL] [Abstract][Full Text] [Related]
29. Priming anticancer active specific immunotherapy with dendritic cells.
Mocellin S
Curr Opin Investig Drugs; 2005 Jun; 6(6):576-81. PubMed ID: 15988908
[TBL] [Abstract][Full Text] [Related]
30. Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer.
Murthy V; Moiyadi A; Sawant R; Sarin R
Curr Mol Med; 2009 Aug; 9(6):725-31. PubMed ID: 19689299
[TBL] [Abstract][Full Text] [Related]
31. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
32. Melanoma: is immunotherapy of benefit?
Faries MB; Morton DL
Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
[No Abstract] [Full Text] [Related]
33. Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting.
Gray A; Yan L; Kast WM
Mol Interv; 2010 Aug; 10(4):197-203. PubMed ID: 20729485
[TBL] [Abstract][Full Text] [Related]
34. Vaccine therapy for renal cancer.
Amato RJ
Expert Rev Vaccines; 2008 Sep; 7(7):925-35. PubMed ID: 18767943
[TBL] [Abstract][Full Text] [Related]
35. TroVax(®) vaccine therapy for renal cell carcinoma.
Zhang RT; Bines SD; Ruby C; Kaufman HL
Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
[TBL] [Abstract][Full Text] [Related]
36. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside.
Morera-Díaz Y; Gavilondo JV; Bequet-Romero M; Sánchez Ramírez J; Hernández-Bernal F; Selman-Housein KH; Perez L; Ayala-Ávila M
Semin Oncol; 2018 Jan; 45(1-2):68-74. PubMed ID: 30318086
[TBL] [Abstract][Full Text] [Related]
37. Paradigm shifts in cancer vaccine therapy.
Schlom J; Gulley JL; Arlen PM
Exp Biol Med (Maywood); 2008 May; 233(5):522-34. PubMed ID: 18375829
[TBL] [Abstract][Full Text] [Related]
38. Vaccination for treatment and prevention of cancer in animal models.
Cavallo F; Offringa R; van der Burg SH; Forni G; Melief CJ
Adv Immunol; 2006; 90():175-213. PubMed ID: 16730264
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma.
Lou E; Marshall J; Aklilu M; Cole D; Chang D; Morse M
Clin Colorectal Cancer; 2006 Jan; 5(5):368-71. PubMed ID: 16512998
[No Abstract] [Full Text] [Related]
40. Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial.
Malkki H
Nat Rev Neurol; 2016 Apr; 12(4):190. PubMed ID: 27020557
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
